EWLS Stock Overview
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Edwards Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$82.64 |
| 52 Week High | US$88.28 |
| 52 Week Low | US$57.94 |
| Beta | 1.07 |
| 1 Month Change | -4.62% |
| 3 Month Change | 22.61% |
| 1 Year Change | 5.92% |
| 3 Year Change | 3.71% |
| 5 Year Change | n/a |
| Change since IPO | 19.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| EWLS | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | 1.6% | 1.8% | 1.6% |
| 1Y | 5.9% | 2.1% | 3.7% |
Return vs Industry: EWLS exceeded the Austrian Medical Equipment industry which returned 2.1% over the past year.
Return vs Market: EWLS exceeded the Austrian Market which returned 3.7% over the past year.
Price Volatility
| EWLS volatility | |
|---|---|
| EWLS Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in AT Market | 5.2% |
| 10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: EWLS has not had significant price volatility in the past 3 months.
Volatility Over Time: EWLS's weekly volatility (4%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 19,800 | Bernard Zovighian | www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.
Edwards Lifesciences Corporation Fundamentals Summary
| EWLS fundamental statistics | |
|---|---|
| Market cap | €49.74b |
| Earnings (TTM) | €1.31b |
| Revenue (TTM) | €5.60b |
38.0x
P/E Ratio8.9x
P/S RatioIs EWLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EWLS income statement (TTM) | |
|---|---|
| Revenue | US$6.00b |
| Cost of Revenue | US$1.38b |
| Gross Profit | US$4.63b |
| Other Expenses | US$3.22b |
| Earnings | US$1.40b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 2.33 |
| Gross Margin | 77.02% |
| Net Profit Margin | 23.35% |
| Debt/Equity Ratio | 8.9% |
How did EWLS perform over the long term?
See historical performance and comparison